News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuon Therapeutics Inc. Announces Positive Topline Results from a Phase 2a Study in Hyperuricemia


6/16/2010 6:25:39 AM

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company’s lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES